Q1 2025 Revenio Group Oyj Earnings Call Transcript
Key Points
- Revenio Group Oyj (FRA:R0V) reported a strong Q1 2025 with net sales of EUR 26.1 million, marking a 10.5% increase from the previous year.
- The company achieved an EBIT of EUR 6.6 million, representing 25.4% of revenue, indicating strong profitability.
- Sales growth was observed across all regions, including the US, APAC, Europe, Middle East, Africa, Latam, and Canada.
- The launch of the new TONOVET pro version and the DRS plus business contributed positively to the company's performance.
- Revenio Group Oyj received FDA approval and CE Certification for its micro perimeter, enhancing its product offerings and market reach.
- The company faces potential impacts from US tariffs, estimated to affect earnings by EUR 0.8 million to EUR 1.4 million in Q3 and Q4 2025 if no mitigating actions are taken.
- Fixed costs increased by 10% year-on-year, partly due to changes in IFRS reporting and increased personnel costs.
- The company is experiencing FX headwinds, which could impact sales and margins.
- There is uncertainty regarding the timeline and costs associated with clinical trials for the eye care (Ilo) based screening solution.
- The SD 500 product, while having good initial reception, is not yet contributing significantly to sales compared to other products like the IC 200.
Good afternoon and welcome to Revenio Group Q1 2025 earnings call. My name is Jouni Toijala. I'm the group CEO and then, as always, we have here as well, Robin Pulkkinen, our, CFO.
Plan for today is to go through the highlights, for the Q1, and, I'll cover that part and then Robin is going to continue, going through the finance sales for the Q1 and then shareholders and financial guidance for 2025, and then we finish up, for the Q&A.
But let's kick off extremely good start for the first quarter. The Q1 was very strong for us in terms of the sales and profitability. Net sales was EUR 26.1 million, up 10.5% from the previous year, â¬23.6 million. If you, look, the currency adjusted growth, so that was 12% EBIT on good level EUR 6.6 million, 25.4% out from revenue.
If you then, go more, to the sales split, so imaging and tonometer, business grew in every region during the Q1, so we got the growth from US, APAC, Europe, Middle East, Africa, Latam, and Canada.
Then if we do a bit
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
